Status:
UNKNOWN
Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
ST Elevation Myocardial Infarction
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Anti-platelet therapy is a key point of acute myocardial infarction (AMI) treatment. Nowadays, dual anti-platelet therapy based on aspirin and ADP-P2Y12 receptor inhibitor is the preferred treatment b...
Eligibility Criteria
Inclusion
- Time after onset of chest pain: ≥ 30 minutes and ≤ 24 hours;
- ST segment elevated ≥ 0.1mV in adjacent two or more leads;
- Scheduled for primary percutaneous coronary intervention without contraindications;
- Written informed consent is obtained.
Exclusion
- Life expectancy ≤ 1 year;
- History of cerebral hemorrhage;
- History of stroke in 6 months;
- Active hemorrhage;
- Severe hepatic and renal dysfunction(ALT \> 3 folds of upper limit of normal, eGFR \< 30ml/min/1.73mm\^2 or Scr \> 200 mmol/L);
- Known hemorrhagic diseases;
- Known malignant tumour diseases；
- Active peptic ulcer disease;
- Blood platelet counts \< 100×10\^9/L;
- Blood hemoglobin \< 90g/L;
- Pregnancy or lactation period；
- Take part in other intervention clinical trials；
- Investigators think not suitable to participate in this trial.
Key Trial Info
Start Date :
May 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03797729
Start Date
May 14 2019
End Date
December 1 2021
Last Update
January 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China, 200032